Search In this Thesis
   Search In this Thesis  
العنوان
Hepcidin: as a biomarker for iron status and inflammation in hemodialysis patients\
الناشر
Ain Shams university.
المؤلف
Ali,Mohamed Saad Mohamed.
هيئة الاعداد
مشرف / محمد محمود عبد الغني
مشرف / ياسر محمود فريد الشهاوي
مشرف / دولت حسين ساني
باحث / محمد سعد محمد علي
الموضوع
Hepcidin. iron status. hemodialysis patients.
تاريخ النشر
2012
عدد الصفحات
p.:144
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
أمراض الكلى
تاريخ الإجازة
1/1/2012
مكان الإجازة
جامعة عين شمس - كلية الطب - Nephrology
الفهرس
Only 14 pages are availabe for public view

from 144

from 144

Abstract

Hepcidin is a circulating peptide hormone encoded by the HAMP (human antimicrobial peptide) gene and mainly produced by the liver. Hepcidin is a negative regulator of iron transport in plasma. The mechanism involved in this regulation is the binding of hepcidin to the iron exporter ferroportin. This binding leads to internalization and degradation of ferroportin, resulting in macrophage iron retention and inhibition of gut iron absorption.
In the absence of apparent inflammation, serum hepcidin levels were faithfully reflected onto serum ferritin levels (an iron storage parameter in maintenance hemodialysis patients). Hepcidin levels respond to inflammation (as an acute-phase reactant), body iron, hypoxia and erythropoiesis. Determination of hepcidin levels in CKD patients may not provide more diagnostic value than ferritin, but further studies are needed.
Hepcidin may in the future improve the targeting and timing of iron therapy by identifying patients during periods of reticulo-endothelial blockage of iron transport, when they would likely not benefit from iron therapy.
In this study, 80 patients on maintenance HD (39 male and 41 female) were concluded, with mean age 50.26_15.87 years (range, 12–79 years), mean duration of HD was 3.5 yrs. rang 1-22 yrs. Among the 80 pts, 20 (25.1%) had CKD as a result of diabetes. Other causes included hypertension 33 pts (40.1%); obstructive uropathy 6 pts (7.7%) and other causes constitute 27.1%.
The study group was divided into 2 groups according to presence or absence of inflammation marketed by HsCRP. Group 1: concluded 30 hemodialysis patients with HsCRP <3 mg/l (no inflammation). Group2: Concluded 50 hemodialysis patients with HsCRP > or=3mg/l (micro-inflammation<15mg/l or real inflammation>15 mg/l).
In both groups we correlated hepcidin with the iron markers (RBCs indices; Hb%, MCV & MCH, reticulocytes, serum iron, and TSAT, ferritin and erythropoietin dose). Also, we correlated hepcidin with the inflammatory markers (high sensitive-CRP, ferritin, WBCs & lymphocytes).
The results Data presented as mean ± SD or median (interquartile range). The study findings revealed; highly positive correlation between hepcidin and ferritin (p<0.001) and negative correlations between hepcidin and Hs CRP (p= 0.475), and between hepcidin and other parameters. Also we found significant correlation between HsCRP with age (p=0.013), ferritin (p=0.004), retics (p=0.038), albumin (p=0.004), Ca (p=0.025) & Ph (p=0.028).